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Background: Pre-eclampsia remains a dominant cause of maternal and fetal mortality in developed countries. In a
previous prospective study we identified a fall in the VEGF-A isoform VEGF-A165b in the plasma of patients in the
first trimester to be a predictor of later pre-eclampsia. VEGF-A165b has been shown to have potent cytoprotective
properties in many cell types. We therefore tested the hypothesis that VEGF-A165b may be cytoprotective for
placental trophoblasts.
Methods: We used an immortalised first trimester trophoblast cell line exposed to chemical toxicity, and
physiological (<2% O2) and atmospheric oxygen (21% O2) in the presence or absence of VEGF-A165b, angiogenic
VEGF-A165a, a non-specific anti-VEGF-A blocking antibody (bevacizumab), or a specific anti-VEGF-A165b antibody. Cell
viability and cytotoxicity were measured by trypan blue and LDH assay respectively.
Results: Under high (21%) levels of oxygen, trophoblast viability was increased, and cytotoxicity reduced by
exogenous recombinant VEGF-A165b (p < 0.05, n = 10) or VEGF-A165a. The cytoprotective effect was not seen under
lower (<2%) oxygen conditions, where VEGF-A165b was upregulated. However inhibition of VEGF-A with blocking
antibodies (bevacizumab or anti-VEGF-A165b) had marked cytotoxic effects under low oxygen conditions presumably
through the blockade of autocrine survival pathways.
Conclusions: These results show that when trophoblasts are exposed to lower oxygen tensions (as they are early in
the 1st trimester) endogenous VEGF-A165b contributes to their survival through an autocrine pathway. In contrast in
high oxygen conditions exogenous VEGF-A isoforms have a greater effect on trophoblast survival.
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Abnormal placental development is central to the patho-
genesis of pre-eclampsia. The early placenta is made up
of microvilli consisting of a mesenchymal core surroun-
ded by cytotrophoblast stem cells that develop into
either overlying syncytiotrophoblasts, or extravillous tro-
phoblasts, which grow out from the placenta. The partial
pressure of oxygen in the normal first trimester placenta
has been found to be lower than 20 mmHg [1], i.e. the
trophoblasts are physiologically used to a lower oxygen
tension than later in pregnancy. At 10–12 weeks of
gestation, trophoblast plugs loosen and oxygenated ma-
ternal blood enters the intervillous space, raising the
oxygen tension [2]. This stimulates trophoblasts to dif-
ferentiate into an invasive phenotype, which are less pro-
liferative and more susceptible to apoptosis [3]. These* Correspondence: David.Bates@nottingham.ac.uk
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unless otherwise stated.processes are regulated by a wide variety of molecules,
including hypoxia-inducible factor-1α (HIF-1α), VEGF
and transforming growth factor-β [4,5].
VEGF-A isoforms play critical roles in the develop-
ment of the placenta. In the first trimester placenta
VEGF-A is present in the cytotrophoblast, syncytiotro-
phoblast and endothelial cells in the villi [6]. Isoforms of
VEGF-A exist in two distinct families, formed by alter-
native mRNA splicing [7]. The canonical isoforms are
generated by splicing of pre-mRNA into the proximal
splice site in exon 8a, after alternative splicing of exons
6 and 7, resulting in a family of isoforms with angioge-
nic activity, termed VEGF-Axxx where xxx refers to the
number of amino acids in the protein (e.g. VEGF-A165,
VEGF-A121). The most widely studied isoform, VEGF-
A165 has pro-angiogenic, pro-permeable and vasodilatory
properties [8]. Alternative splicing in exon 8, 66 bases
downstream in the pre-mRNA results in a family of iso-
forms, termed VEGF-Axxxb, which differ in their final six. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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and VEGF-A189b can be generated as sister isoforms of
the canonical isoforms [9]. VEGF-A165b and VEGF-A121b
are anti-angiogenic in vivo. VEGF-A165b, the most exten-
sively studied isoform, binds to and activates VEGF-R2,
but is quantitatively and qualitatively different from
VEGF-A165a [10], stimulating cyto-protective signal-
ling, but not angiogenic pathways [11,12]. In terms of
cell survival therefore, VEGF-A165a and VEGF-A165b
often have the same rather than contrasting properties.
Although evidence is mounting for the expression and
role of VEGF-A165a in placental tissue, little is known
about the expression and function of placental VEGF-
A165b, in particular the effect of this alternatively spliced
anti-angiogenic isoform on trophoblast survival. This is
in contrast to the recent demonstration of the anti-
angiogenic role of VEGF-A165b in skin in patients with
systemic sclerosis [13].
The foundations of pre-eclampsia are laid down in the
first trimester, with inadequate invasion of placental tro-
phoblasts into the maternal uterine spiral arteries. In the
first trimester, women who were later to develop pre-
eclampsia had lower levels of plasma VEGF-A165b than
pregnant women who remained normotensive through-
out pregnancy [14]. The finding that VEGF-A165b is
cyto-protective for some cell types, led us to test the hy-
pothesis that VEGF-A165b may contribute to trophoblast
survival at a crucial time in the first trimester and defi-
ciency of the molecule may prevent trophoblast well-
being and the successful physiological process of spiral
artery remodelling by trophoblast cells.Methods
Cell culture
Cell viability and cytotoxicity assays were performed on
HTR-8/SVneo cells, a human trophoblast cell line im-
mortalised using SV40 (Simian Virus 40) large T antigen
(Tag), a kind gift from Charles H. Graham, University of
Toronto, who first established this cell line [15]. These
cells can proliferate indefinitely, and have been shown to
retain many of their phenotypic features of the non-
transfected parent trophoblast cells such as staining for
cytokeratin [16]. They are however, a transformed cell
line, rather than a primary trophoblast culture.
These cells were cultured in sterile filtered RPMI 1640
media supplemented with 5% fetal bovine serum and 1%
penicillin/streptomycin (RPMI/5%FBS/1%PS). Cells were
incubated in atmospheric oxygen conditions (5% CO2
and 21% O2) at 37ºC in T25 flasks, starting at passage
78 and split twice weekly. HTR8/SVneo cells were cul-
tured in RPMI/5%FBS/1%PS for at least 2 weeks to
super-confluency, and formed the villous trophoblast
cell columns that characterise this cell type.Cytoprotection assay
HTR-8/SVneo cells were plated onto 6-well cell culture
plates at a density of 1x105 with 2 ml RPMI/5%FBS/1%
PS and incubated at 37ºC in 21% O2. After 24 hours the
cells were rinsed in 2 ml 1xPBS and the media replaced
with serum free RPMI 1640 supplemented with or with-
out VEGF-A165b 40 ng/ml. After 48 hours of incubation
at 37ºC media was harvested and centrifuged at 3000 rpm
for 3 minutes. The resulting pellets consisted of dead
HTR-8/SVneo cells, which were resuspended in 1 ml of
RPMI. The remaining live cells on the surface of the wells
were removed by trypsinisation (1 ml trypsin solution per
well), and 2 ml RPMI added to inactivate the trypsin.
Following centrifugation of the contents of the well at
3000 rpm for 3 minutes, the supernatant was removed
and the pellet of live cells was resuspended in the dead
cell solution to mix both live and dead cells together.
The solution was pipetted thoroughly and 100 μl was
transferred to an eppendorf containing 100 μl of 0.4%
Trypan blue (400 mg trypan blue in 100 ml 1xPBS).
Trypan blue dye is able to pass through the cell mem-
brane of dead, but not live cells. The % viability of cells
after treatment with agents was calculated as:
100Live Cells= Dead CellsþLive Cellsð Þ
Lactate Dehydrogenase (LDH) assay for cytotoxicity
The LDH assay (CytoTox 96, Promega) was carried out
according to manufacturer’s instructions. Cells grown
to 90-95% confluency were seeded onto 96-well sterile
cell culture plates at a density of 3 × 104 cells per well
and 100 μl RPMI/5%FBS/1%PenStrep was added to each
well before incubation at 37ºC. After 24 hours the media
was removed, and wells were washed with 1 × PBS once
before fresh serum free media was added (100 μl/well).
The following treatments were added to the wells: 1nM
or 2nM of rhVEGF-A165 or VEGF-A165b, an antibody
against VEGF-A bevacizumab (25nM), or a VEGF-A165b
antibody: clone 56–1 (R&D systems MAB3045), at 25 or
50 nM. Control wells contained serum free media only
and the positive control wells contained 5 mM sodium
butyrate, a known cytotoxicity inducing agent. No IgG
control was included. Plates were incubated in 21%O2 at
37ºC. After 48 hours media (50 μl/well) was collected
from wells and transferred to fresh 96-well plates for the
later quantification of LDH concentration in the media
after 48 hours of treatment. The original culture plates
with their 50 μl/well of remaining media was then freeze-
thawed at –80ºC and then 50ºC to lyse the HTR-8/SVneo
cells. The resulting cell lysates were collected and trans-
ferred onto fresh 96-well plates (lysate) and both media
and lysate plates were centrifuged at 1500 rpm for 10
minutes. 50 μl/well of solution in each well on both sets
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which the detection substrate tetrazolium salt was
added for 30 minutes. Visible wavelength absorbance
data were measured in a plate reader. The % cytotoxicity
was calculated as:
100  ODmedia = ODmedia þ ODlysate
 
LDH assays were repeated in triplicate and performed
in physiological (<2% O2) as well as atmospheric (21%
O2) conditions.ELISA
Cells were lysed using RIPA lysis buffer containing
protease inhibitors and the protein concentration was
measured using Precision Red (Cytoskeleton, Inc), ac-
cording to the manufacturer’s guidelines. Pan-VEGF
and VEGFxxxb ELISA was performed using the VEGF
DuoSet ELISA kit DY293 and DY3045, respectively
(R&D Systems, Abingdon, UK). This VEGF-Axxxb ELISA
should detect all the VEGF-Axxxb isoforms, but not
the VEGF-Axxx isoforms, but the affinity of the anti-
bodies to the ‘minor’ isoforms such as VEGF-A121b and
VEGF-A189b has not been determined. Briefly, 1 μg/ml
goat anti-human pan-VEGF or 2 μg/ml anti-human
VEGFxxxb (Clone 56/1) were used as capture antibodies,
overnight at room temperature (RT). After washing
and blocking steps, serial dilutions of, rhVEGF165 or
rhVEGF165b standards were added to each well in tripli-
cate, at concentrations ranging from 15.625 pg/ml to
4 ng/ml. Sample lysates were typically diluted 1:5 in block-
ing solution and added in duplicate to each well. Either bi-
otinylated goat anti-human VEGF (0.1 μg/ml), or mouse
anti-human VEGFxxxb (0.25 μg/ml), was used as detection
antibody. Absorbance was read in a plate reader Opsys
MR 96-well plate reader (Dynex Technologies, Chantilly,
VA, USA) at 450 nm, with the control reading at 570 nm.
Revelation Quicklink 4.25 software was also used to con-
struct a standard curve from mean absorbance values of
standards enabling the estimation of VEGF concentration
for each sample.Cell culture under reduced oxygen tension
The method of achieving low oxygen tension (<2%) has
been described previously [17]. Cells were cultured in a
hypoxia chamber (Sensotec GB300) to which a gaseous
mix of 95% N2 and 5% CO2 (BOC) was connected at
20 l/min for 5 minutes and changed 12 hourly. Oxygen
concentration was assessed after 12 hours using an oxy-
gen monitor (Cambridge Sensotec GB300) and confirmed
an oxygen reading of <2% O2.Statistics
Comparisons between VEGF-A165b treated (test) tropho-
blast cells were made with the serum free media (control)
trophoblast cells. Statistical analyses of cell culture data
were made using Unpaired t tests and one way ANOVAs,
with p < 0.05 regarded as significant. Values are expressed
as means ± S.E.M.Results
VEGF-A165b is cytoprotective for trophoblasts
To determine whether exogenous VEGF-A165b was cyto-
protective for placental trophoblasts, 1 × 105 HTR-8/
SVneo trophoblast cells were cultured in serum free me-
dium (SFM) ± 1nM VEGF-A165b for 48 hours in at-
mospheric oxygen (n = 10). Viability of cells exposed to
VEGF-A165b, measured by trypan blue exclusion, was in-
creased by 21% compared to control conditions (viability
75% ± 2.8 vs. 54% ± 8.1, Unpaired t test, p < 0.05, n = 10,
Figure 1A). The LDH assay was then used to determine
if VEGF-A165b increases trophoblast survival in a dose
dependent manner. 19 wells were treated for 48 hours
with SFM, SFM+ 1nM VEGF-A165b or 2nM VEGF-A165b
in 21% O2. A dose dependent decrease in cytotoxicity
occurred (% cytotoxicity 33.6% ± 0.6, 29.2% ± 0.9, and
24.2% ± 3.5 respectively, One way ANOVA, p = 0.0019,
Dunnett’s Multiple Comparison Test, Figure 1B). This
was similar to that induced by VEGF-A165a – cytotoxicity
decreased from 26.5 ± 2.4% in SFM to 20.7 ± 3.3% when
cultured in 2nM VEGF-A165a (Unpaired t test, p < 0.05,
n = 13, Figure 1C). To determine whether VEGF-A165b
could prevent chemically induced cytotoxicity, 3 × 104
trophoblast cells were cultured with 5 mM sodium butyr-
ate ± 1nM VEGF-A165b. Pre-incubation of the cells with
1nM VEGF-A165b for two days significantly decreased Na
butyrate- induced cell death (cytotoxicity 58% ± 2.7 vs.
39% ± 3.2, Unpaired t test, p < 0.05, n = 8, Figure 1D).Lower oxygen tensions abolish the effect of exogenous
VEGF-A on trophoblast survival
In the early placental environment, before 10 weeks of
gestation, trophoblasts experience lower oxygen tensions
of less than 20 mmHg (2.5%) [1] and VEGF-A expres-
sion has been shown to be induced by such low oxygen
tensions [18]. We therefore determined whether low oxy-
gen tension itself was cytoprotective by inducing VEGF-A
expression. Immortalised HTR-8/SVneo first trimester
trophoblast cells were cultured for 48 hours in serum free
media (SFM) 21% O2 or <2% O2 conditions. The LDH as-
say was used to determine cell cytotoxicity. After 48 hours,
cytotoxicity was reduced in the cells exposed to lower oxy-
gen conditions (17.8% ± 2.6) compared to cells exposed to
atmospheric oxygen (33.7% ± 0.63, n = 16, Unpaired t test,
p < 0.0001, Figure 2A).
Figure 1 Exogenous VEGF-A is cytoprotective for trophoblasts in atmospheric oxygen conditions. A. HTR-8/SVneo (first trimester immortalised
trophoblast) cells were cultured for 48 hours in SFM ± 1nM VEGF-A165b and survival assessed by Trypan exclusion. (* = p < 0.05, Unpaired t test, n = 10).
B. Cytotoxicity assessed by LDH release (n = 19, One way ANOVA, p = 0.0019, Dunnett’s Multiple Comparison Test). C. Trophoblasts were cultured in
SFM± 2nM VEGF-A165a in 21% O2. After 48 hours cytotoxicity determined by LDH assay. (Unpaired t test, p < 0.05, n = 13). D. In the presence of 5 mM
sodium butyrate (NaBu, a cytotoxic agent), addition of 1 nM VEGF-A165b significantly decreased the trophoblasts cytotoxicity (p < 0.05, Unpaired
t test, n = 8).
Figure 2 First trimester trophoblast cells are resistant to low oxygen tensions. 1A. Trophoblasts were cultured in 21% O2 or with reduced
oxygen (<2%O2) conditions for 48 hours in serum free media (SFM) and cytotoxicity assessed by LDH release (Unpaired t test, p < 0.0001, n = 16).
B. Trophoblasts were cultured for 48 hours in SFM or 2nM VEGF-A165b in <2% O2 and cytotoxicity assessed by LDH release (Unpaired t test
p = 0.13, n = 13). C. Trophoblasts cytotoxicity assessed by LDH release in cells treated with 2nM VEGF-A165a under lower oxygen conditions.
D. Trophoblasts were cultured for 48 hours in low or atmospheric oxygen conditions. ELISA showed that VEGF-A165b expression was increased
by lowering pO2 (1812 pg/ml ±33 vs. 1407 pg/ml ±95, Unpaired t test, p = 0.016).
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tect cells in lower oxygen conditions, HTR-8/SVneo cells
were treated with 1nM VEGF-A165b in SFM for 48 hours
in <2% O2. This had no effect on cytotoxicity. To ensure
that this was not due to an altered responsiveness of the
cells, a separate set of cells were treated with or without
2 nM VEGF-A165b, which also had no effect on cyto-
toxicity (n = 21, Unpaired t tests, p = 0.2 Figure 2B). To
determine whether VEGF-A165a was able to reduce cy-
totoxicity, cells were treated with 2nM VEGF-A165a
in <2%O2. Again no reduction in cytotoxicity was seen
(Figure 2C). This suggested that either the cells were no
longer able to respond to VEGF-A, that they had already
reached a maximal reduction in cytotoxicity, or that the
cells were producing endogenous VEGF-A, and that this
was acting sufficiently in an autocrine manner. We there-
fore measured VEGF-A165b levels in 1 × 10
5 HTR8/SVneo
cells incubated in either <2% O2 or atmospheric oxygen.
After 48 hours, cells were harvested, protein extracted and
expression of VEGF-A165b in cell lysate measured by
ELISA. VEGF-A165b from low oxygen treated trophoblasts
was significantly increased compared to cell lysate from
trophoblasts cultured in 21%02, when measured by ELISAFigure 3 Endogenous VEGF165b is cytoprotective when pO2 < 2%. A. T
(to inhibit all VEGF-A isoforms, n = 7) or 50nM anti-VEGF-A165b (clone 56/1,
hypoxia chamber (<2%O2) and cytotoxicity measured. (One way ANOVA, p
cultured in SFM ± 50nM anti-VEGF-A165b in 21% 02 for 48 hours and cytoto
significantly increased in cells exposed to 25nM VEGF-A inhibitor bevacizuma
test with Welch correction, p > 0.05).(1.8 ± 0.033 ng/ml vs. 1.4 ± 0.095 ng/ml respectively, Un-
paired t test, p = 0.016, Figure 2D).
In low oxygen conditions, inhibition of total VEGF-A via
Bevacizumab, or exclusively VEGF-A165b increases
cytotoxicity
If endogenous VEGF-A is responsible for the reduction
in cytotoxicity under low oxygen conditions, then inhib-
ition of endogenous VEGF-A should be cytotoxic. In a
series of 20 experiments, 3 × 104 HTR-8/SVneo cells
were cultured in SFM ± 25nM Bevacizumab (to inhibit
all VEGF-A isoforms), or 25nM of an anti-VEGF-A165b
monoclonal antibody (clone 56–1), to inhibit VEGF-A165b
only, leaving VEGF-A165a active. Following incubation for
48 hours in a hypoxia chamber (<2% O2), an LDH assay
was performed and cytotoxicity was expressed as relative
LDH concentration in the media compared to lysate.
Baseline cytotoxicity in SFM was 17.8 ± 2.6%. When cul-
tured in Bevacizumab, cytotoxicity rose to 26.4 ± 1.6%,
and was even higher when exposed to clone 56–1, 30.8 ±
2.7% (One Way ANOVA, p = 0.0068, Dunnett’s Multiple
Comparison’s Test, Figure 3A). To determine whether this
cytotoxicity was oxygen dependent, 3 × 104 HTR-8/SVneorophoblasts were cultured in SFM (n = 5) ± Bevacizumab 25nM
AbCam) to inhibit only VEGF-A165b isoforms, n = 8) for 48 hours in a
= 0.0068, Dunnett’s Multiple Comparison Test). B. Trophoblasts were
xicity assayed. (Unpaired t test p = 0.6, n = 14). C. Cytotoxicity was not
b (n = 23) compared with control conditions in SFM (n = 26, Unpaired T
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cizumab or 50 nM anti-VEGF-A165b in 21% O2. After
48 hours, the media and cell lysate were harvested for the
quantification of LDH, and cytotoxicity was calculated.
There was no significant difference in cell death following
exposure to the anti-VEGF-A165b antibody compared to
control conditions (Unpaired t Test, p = 0.6, n = 14), and a
small but not statistically significant increase following
exposure to Bevacizumab for 48 hours (31.4 ± 1.8% vs.
27.6 ± 0.8%, Unpaired t test, p = 0.0599, n = 49, unpaired t
test with Welch correction for unequal variance, F test to
compare variances p = 0.0009, Figure 3B&C).
Discussion
We show here that trophoblasts thrive in low oxygen
conditions partly by inducing VEGF-A expression result-
ing in an autocrine cytoprotective mechanism that is
specific for the anti-angiogenic isoforms such as VEGF-
A165b. In early placentation, extravillous trophoblasts
differentiate from a proliferative to an invasive pheno-
type [19]. As these extravillous trophoblasts invade the
maternal blood vessels they form plugs; groups of cells
that occlude the spiral arteries and prevent oxygenated
maternal blood from entering the intervillous space
while the spiral arteries remodel to generate low resist-
ance vessels that will provide maternal blood to the pla-
centa [20]. Up to 10 weeks of gestation, the trophoblast
cells therefore exist in a lower oxygen environment, and
this results in the trophoblasts maintaining a prolife-
rative, non-invasive phenotype [21]. Thus, the results
presented here provide a potential cellular mechanism
through which the trophoblasts in normal pregnancy
could survive the low oxygen levels induced by their
plugging of the spiral arteries.
If this upregulation of VEGF-A165b does not occur
then the trophoblasts will suffer more cell death. In nor-
mal placental tissue, tightly regulated processes of pro-
liferation and cell death occur continuously. Cell death
may be apoptotic (programmed cell death, where organ-
elles are packaged up to be phagocytosed), or necrotic,
which involves the cytoplasm and organelles being shed
into the extracellular matrix without any expenditure
of cellular energy [22]. In pre-eclampsia, trophoblasts
undergo increased rates of apoptosis [23,24], and pre-
eclamptic trophoblasts are more susceptible to stressful
events such as TNF- α exposure, which induces apop-
tosis [25]. It is known that certain growth factors such
as epidermal growth factor (EGF) can rescue tropho-
blasts from apoptosis [26]. Furthermore, in 2002 Smith
et al. showed that insulin-like growth factor-1 (IGF-1),
basic fibroblast growth factor (bFGF), and platelet de-
rived growth factor AA (PDGF-AA) were also able to
partially inhibit apoptosis induced by TNF- α and IFN-β,
although VEGF-A165 was not able to do so [27]. The datapresented here shows for the first time that the anti-
angiogenic but cyto-protective isoform VEGF-A165b can
act as a survival factor, as it rescued trophoblasts from so-
dium butyrate induced cell death. They also suggest that a
lack of VEGF-A165b expression early in pregnancy, as is
seen in women that go onto develop pre-eclampsia, might
result in increased cell death, and hence contribute to the
development of pre-eclampsia.
The expression of the pro-angiogenic factors VEGF-A
and PlGF has been demonstrated in first trimester hu-
man trophoblast and placentae [17,28]. Those authors
showed that during low oxygen conditions (correspond-
ing to before 10 weeks of gestation) the expression of
VEGF-A was significantly up-regulated by 8-fold in com-
parison to atmospheric conditions, while PlGF expres-
sion was reduced under low oxygen tensions. However,
they did not use probes or antibodies that would distin-
guish between the proangiogenic isoforms (VEGF-A121a
VEGF-A165a, VEGF-A189a) or the anti-angiogenic iso-
forms (VEGF-A121b, VEGF-A165b, or VEGF-A189b).
The mechanism of action of VEGF-A165b on cytopro-
tection is still not yet clear. The expression of all three
VEGF-A receptors (VEGFR1 or Flt-1, VEGFR2 or KDR,
and VEGFR3) has been demonstrated in trophoblast cells
[28,29]. VEGF-A165a exerts its effects through VEGFR-2,
whereas VEGF-A165b has been shown to act by preventing
VEGF-A165a acting on VEGFR2 and by acting directly on
VEGFR1 in podocyte epithelial cells and endothelial cells.
Recently, VEGF-A165b has been shown to act as a cytopro-
tective agent on retinal pigmented epithelial cells and neu-
rons through VEGFR2 but its mechanism of action on
trophoblast survival is not yet known.
This work shows that VEGF-A165b addition to cultured
trophoblasts in high oxygen conditions reduces cytotox-
icity, and although addition of VEGF-A165b to cells under
low oxygen conditions does not increase survival, specific
inhibition of the VEGF-A165b isoform increases tropho-
blast death, suggesting that VEGF-A165b is a trophoblast
survival factor both when administered exogenously in
conditions of high pO2, and via an autocrine pathway dur-
ing low pO2. The measured increase in VEGF-A165b dur-
ing low pO2 was relatively small (30%), but it is difficult to
extrapolate from this to the local concentration at the cell
membrane. This work also shows that low pO2 increases
the expression of VEGF-A165b by trophoblast cells in cul-
ture, suggesting that exogenous VEGF-A165b does not
reduce cell death under low pO2 because endogenous
VEGF-A165b, present in abundance, is already fulfilling
the survival role. However, because the anti-VEGF-A165b
antibody inhibits endogenous VEGF-A165b, a resulting in-
crease in trophoblast cytotoxicity was observed. It is there-
fore likely that under low pO2 conditions VEGF-A165b
isoforms play the more important role in trophoblast
survival, and the finding that low pO2 stimulates the
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ever, although total VEGF-A inhibition and specific inhib-
ition of VEGF-A165b had similar effects, this does not rule
out an overlapping role for VEGF-A165a. In addition, this
work demonstrates reduced trophoblast death in low pO2,
and increased cytotoxicity with VEGF-A165b inhibition.
Therefore, the reduction of VEGF-A165b at 12 weeks of
gestation seen in the plasma of women who will later
develop pre-eclampsia may be reflecting an (as yet) un-
identified pathological process in the trophoblasts, which
prevents trophoblasts from producing sufficient VEGF-
A165b, which if secreted in adequate amounts would help
to promote trophoblast survival, and these increased levels
would be reflected in the plasma. Thus under normal
pregnancy conditions, the trophoblast survival in the uter-
ine spiral artery plugs enables the appropriate remodelling
of the artery to a low resistance vessel capable of providing
sufficient maternal blood to the placenta. If the tropho-
blasts do not produce sufficient VEGF-A165b then they
would undergo apoptosis in the low oxygen conditions of
the first trimester, and the plug would be unsustainable,
and hence not allow the arteries to undergo appropriate
remodelling.
The above hypothesis makes a number of assumptions
that should be made clear. First, the oxygen tension in
the trophoblasts in vivo rises from 18 mmHg (2.5%) at
8 weeks to 40 mmHg (5%) at 10 weeks, and then to
90-100 mmHg (11-13%) at later time points. Thus 21%
oxygen is hyperoxic for trophoblasts, in vivo. It will
therefore be important to determine in a more physiolo-
gically relevant model (such as isolated perfused placenta),
the effects of increasing oxygen tension on cytotropho-
blast survival. Secondly, the effects of low oxygen tension
are likely to be complex at tensions lower than 2%. It is
possible that very low oxygen levels (e.g. <0.1%) may in-
duce a true “hypoxia” in trophoblasts, and the effect of
this on VEGF splicing has not been determined. We were
unable to regulate the oxygen levels below 2% due to the
sensitivity of the sensor, so it is possible that lower oxygen
tensions were seen. Finally, trophoblasts grown in culture
are unlikely to behave as they do in vivo, and so the ex-
trapolation of these data to human physiology must by
definition be speculative, but these findings provide a ra-
tionale for a more in depth investigation using intact pla-
cental tissues. Moreover, further work is now necessary to
determine whether VEGF-A165b is able to induce the inva-
sive properties of trophoblast cells. In addition, the LDH
assay does not differentiate between necrosis and apop-
tosis. Future experiments using more specific methods
such as flow cytometry are required, as this would allow
the effect of VEGF-A165b on the entire trophoblast cell
cycle to be determined. Moreover, we did not compare
bevacizumab or anti-VEGF-A165b antibodies to a control
IgG, as the former is a human and the latter a mouseantibody. Previous studies have shown that treatment
of trophoblasts with IgG by itself has no effect on tropho-
blast cell death [30], but further experiments should in-
clude this as a control. Finally, these experiments have not
yet clarified the relative functional effects of the pro- and
anti-angiogenic VEGF-A isoforms on trophoblast prolifer-
ation and invasion, including which isoform is the more
important depending on the oxygen tension of the envir-
onment. Co-culture experiments with decidua and tro-
phoblast, at differing oxygen tensions and exposure to
different doses of the two VEGF-A isoforms are now re-
quired, as it is not yet possible to make a leap from effects
of exogenous and endogenous VEGF in culture to the ef-
fects of VEGF isoforms in humans.
Conclusion
These experiments have shown that low pO2 increases
the production of VEGF-A165b by placental trophoblasts,
and that blocking VEGF-A165b under these conditions
leads to trophoblast cell death. Therefore VEGF-A165b
may be a survival factor for trophoblasts during the first
trimester of pregnancy, such that VEGF-A165b defi-
ciency may decrease the ability of trophoblasts to survive
and subsequently invade the maternal spiral arteries dur-
ing the physiological process of spiral artery remodelling.
It is well established that inadequate spiral artery remodel-
ling is associated with the development of pre-eclampsia
later in the pregnancy. These molecular findings of re-
duced VEGF-A165b being associated with trophoblast
toxicity in the (physiologically) low oxygen levels of
first trimester of pregnancy positively corresponds to
the previously reported finding that women who eventu-
ally develop pre-eclampsia have reduced plasma levels of
VEGF-A165b during their first trimesters. These findings
may imply a time and anatomical specific VEGF-A165b de-
ficiency in the pathophysiology of pre-eclampsia.
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